Practice and evaluation of pharmacists’participation in long-term MTM models for stroke patients based on family doctor system
- VernacularTitle:家庭医生制度下药师参与脑卒中患者长期药物治疗管理模式实践及评价
- Author:
Lu SHI
1
;
Chun LIU
1
;
Lian TANG
1
;
Jingjing LI
1
;
Sudong XUE
1
;
Yanxia YU
1
;
Wenwen LI
2
;
Keren YU
3
;
Jianhui XUE
4
;
Wen MA
5
;
Hongzhi XUE
1
Author Information
1. Dept. of Pharmacy，the Affiliated Suzhou Hospital of Nanjing Medical University，Jiangsu Suzhou 215002，China
2. Dept. of Primary Health and Aging Health，Suzhou Municipal Health Commission，Jiangsu Suzhou 215002，China
3. Dept. of Pharmacy，Suzhou Runda Community Hospital，Jiangsu Suzhou 215007，China
4. Dept. of Information，Suzhou Hospital Affiliated to Nanjing Medical University，Jiangsu Suzhou 215002，China
5. School of Pharmacy，Nanjing Medical University，Nanjing 211166，China
- Publication Type:Journal Article
- Keywords:
family doctor system;
clinical pharmacist;
community pharmacist;
stroke;
pharmaceutical care;
medication
- From:
China Pharmacy
2025;36(9):1129-1134
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the clinical efficacy of integrating pharmacists into family health teams （FHTs） for long-term medication therapeutical management （MTM） in stroke patients， and empirically evaluate the service model. METHODS A pharmacist team， jointly established by clinical and community pharmacists from the Affiliated Suzhou Hospital of Nanjing Medical University （hereinafter referred to as “our hospital”）， developed a pharmacist-supported MTM model integrated into FHTs. Using a prospective randomized controlled design， 170 stroke patients discharged from our hospital （July 2022-December 2023） and enrolled in FHTs at Suzhou Runda Community Hospital were randomly divided into trial group （88 cases） and control group （82 cases） according to random number table. The control group received routine FHTs care （without pharmacist involvement in the team collaboration）， while the trial group xhz8405@126.com received 12-month MTM services supported by pharmacists via an information platform. These services specifically included innovative interventions such as personalized medication regimen optimization based on the MTM framework， dynamic medication adherence management， medication safety monitoring， a home medication assessment system， and distinctive service offerings. Outcomes of the 2 grousp were compared before and after intervention， involving medication adherence （adherence rate， adherence score）， compliance rates for stroke recurrence risk factors [blood pressure， low-density lipoprotein cholesterol （LDL-C）]， and incidence of adverse drug reactions （ADR）. RESULTS After 12 months， the trial group exhibited significantly higher medication adherence rates， improved adherence scores， higher compliance rates for blood pressure and LDL-C targets compared to the control group （P＜0.05）. The incidence of ADR in the trial group （4.55%） was significantly lower than that in the control group （8.11%）， though the difference was not statistically significant （P＞ 0.05）. CONCLUSIONS Pharmacist involvement in FHTs to deliver MTM services significantly enhances medication adherence and optimizes risk factor for stroke recurrence， offering practical evidence for advancing pharmaceutical care in chronic disease management under the family doctor system.
